Table 2

Characteristics of the nine randomised controlled trials of tumour necrosis factor (TNF) blockers included in the meta-analysis comparing serious infections with versus without TNF blockers

Sources (reference)Number of randomised patientsNumber who completed follow-upStudy protocol with doses (number of patients in each group)Duration of trial (weeks)
Braun et al247065Infliximab 5 mg/kg at weeks 0, 2, 6 (35)12
Placebo (35)
Marzo-Ortega et al284235Infliximab 5 mg/kg at weeks 0, 2, 6, 14, 22 + methotrexate 7.5 mg/week (28)30
Placebo + methotrexate 7.5 mg/sem (14)
van der Heijde et al22279274Infliximab 5 mg/kg at weeks 0, 2, 6, 12, 18 (201)24
Placebo (78)
Brandt et al193332Etanercept 25 mg twice weekly (16)30
Placebo (17)
Calin et al258482Etanercept 25 mg twice weekly (45)12
Placebo (39)
Davis et al26277246Etanercept 25 mg twice weekly (138)24
Placebo (139)
Gorman et al34037Etanercept 25 mg twice weekly (20)16
Placebo (20)
van der Heijde et al21356312Etanercept 50 mg per week (155)12
Etanercept 25 mg twice weekly (150)
Placebo (51)
van der Heijde et al2315296Adalimumab 40 mg per 2 weeks (208)24
Placebo (107)